BioSpace News Archive

Drug Development

Pfizer’s $5.4B GBT Bet Pays Off with Promising Phase II Data for Oxbryta Successor

Patients treated with the investigational sickle cell therapy saw an increase in hemoglobin levels and improved red blood cell parameters.

December 11, 2023
·
3 min read
·
Tristan Manalac
Drug Development

Roche Partner Poseida Touts High Response Rates for Allogeneic CAR-T Therapy

The investigational allogeneic CAR-T therapy P-BCMA-ALLO1 appears to be more effective following strong immunosuppressive preconditioning.

December 11, 2023
·
2 min read
·
Tristan Manalac
ASH 23: CAR-T for Autoimmune, Arcellx’s Multiple Myeloma Challenger and Seagen’s Combo Play

A CAR-T cell therapy for autoimmune diseases generated significant attention at the 2023 American Society of Hematology (ASH) annual meeting and Arcellx and Seagen posted promising data.

December 11, 2023
·
3 min read
·
Kate Goodwin
Bluebird’s Newly Approved SCD Gene Therapy Faces Rough Road with Hefty Price Tag, Boxed Warning

These factors, along with bluebird bio’s failure to receive a priority review voucher, all hurt the company’s stock price following Lyfgenia’s approval.

December 11, 2023
·
2 min read
·
Tristan Manalac
Drug Development

Regeneron Presents Positive Phase II Results for its Lymphoma Drug

The New York-based pharma reported at ASH that odronextamab had an 80% objective response rate, with 73% of patients experiencing a complete response.

December 11, 2023
·
2 min read
·
Tyler Patchen
Business

Amid Revenue Downturn and Staff Cuts, Catalent Looks to GLP-1

The company’s fiscal report for 2023 details revenue losses of $539 million and layoffs of 1,100 employees but notes that future GLP-1 manufacturing revenues could help stabilize its finances.

December 11, 2023
·
2 min read
·
Connor Lynch
Lilly Stock Slips as Patients Regain Weight After Stopping Zepbound

The Indiana-based pharma shed shares after a study published Monday in JAMA showed “substantial” weight gain after patients discontinued treatment with the GLP-1 receptor agonist.

December 11, 2023
·
2 min read
·
Connor Lynch
Drug Development

Long-Term Data for Kite’s Yescarta® CAR T-Cell Therapy Presented at ASH 2023 Demonstrate High Rate of Durable Response in Patients With High-Risk Large B-Cell Lymphoma

Kite, a Gilead Company (Nasdaq: GILD), today announced results from a three-year follow-up analysis of ZUMA-12, a Phase 2 study of Yescarta® (axicabtagene ciloleucel) as first-line treatment after two cycles of chemoimmunotherapy in patients with high-risk, large b-cell lymphoma (LBCL).

December 11, 2023
·
18 min read
BioCT Names Dr. Stephen Bloch its 2023 Entrepreneur of the Year

BioCT, the life sciences trade association for Connecticut, is thrilled to name Stephen Bloch, MD, the 2023 BioCT Entrepreneur of the Year, an award recognizing individuals who are imaginative, passionate, and game-changers in Connecticut bioscience.

December 11, 2023
·
3 min read
Pharm Country

CSL Behring’s HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B

Global biotechnology leader CSL announced the three-year results from the pivotal HOPE-B study confirming continued long-term durability and safety of HEMGENIX® following a one-time infusion in people living with hemophilia B.

December 11, 2023
·
11 min read